Clinical Trials Logo
NCT number NCT03494946
Study type Interventional
Source Oslo University Hospital
Contact Svein Dueland, PhD
Phone +4722934000
Email svedue@ous-hf.no
Status Recruiting
Phase N/A
Start date December 5, 2016
Completion date January 2027

Clinical Trial Summary

The trial is a randomized control trial. Patients are randomized between Ltx and other treatment that may include further chemotherapy, TACE, SIRT or other available treatment options. The patients will be randomized 1:1 to Ltx and chemotherapy/other treatment options.


Clinical Trial Description

Patients with non-resectable CRC liver metastases evaluated at the liver MDT at Oslo University Hospital, Rikshospitalet will be included in the study. Patients should have progressive disease on 1.line chemotherapy or the treatment should have been stopped due to toxicity. Patients randomized to Ltx will if applicable stop bevazicumab. All patients (both arms) will start further treatment that may include chemotherapy, TACE, SIRT or other available treatment options. Patients not receiving a donor liver graft within 3 months after listing for transplantation will be taken off the waiting list and transferred to the chemotherapy/other treatment option group. Patients randomized to Ltx and developing progressive disease beyond the inclusion/exclusion criteria during the time on the waiting list will be excluded from the study and receive best treatment option at the discretion of the treating physician.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT02963831 - A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Recruiting NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Enrolling by invitation NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Navigation N/A
Recruiting NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
Completed NCT01266564 - An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer N/A
Recruiting NCT03422432 - Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases N/A
Recruiting NCT03214939 - Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Colorectal Cancer Early Phase 1
Active, not recruiting NCT01688232 - The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer N/A
Active, not recruiting NCT00578721 - Trial of Aspirin and Arginine Restriction in Colorectal Cancer Phase 2
Recruiting NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Terminated NCT02277093 - Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer Phase 2
Recruiting NCT03070574 - Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome Phase 2
Not yet recruiting NCT03083951 - Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL) Phase 4
Recruiting NCT02893540 - Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC Phase 2/Phase 3
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Recruiting NCT02895464 - Feasibility of Home-based Preoperative Exercise in Older People N/A
Recruiting NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Recruiting NCT02531620 - Prehabilitation in Elective Colorectal Resection: A Pilot Study (Prehab) N/A